Abstract: Disclosed are the skin care applications of a composition containing the partially purified extracellular metabolite isolated from Bacillus coagulans MTCC 5856. More specifically, the invention discloses the ability of the partially purified extracellular metabolite isolated from Bacillus coagulans MTCC 5856 to confer protection to the skin fibroblasts against UV induced cell damage and apoptosis, oxidative stress and inflammation.

Abstract: The present disclosure relates to a harvesting system for variety of grain crops. The harvesting system comprises a harvester control unit, a grain loss monitoring GLM-ECU, a cloud communication interface ECU, a plurality of sensors, a controller area network (CAN), a buzzer/alarming device, a display unit, a cloud and a mobile application. The GLM-ECU is configured to process signals from a sieve sensor and a straw walker sensor. The harvester control unit is configured to process signals received from the plurality of sensors and the cloud communication interface ECU serves as an interface to interchange the data between the harvester control unit and the cloud . The harvester system results in increase in productivity and trust among the stake holders by virtue of real-time information sharing.

Abstract: The present invention discloses the potential of probiotic bacteria Bacillus coagulans individually or in combination with multi-enzyme complex for reducing gluten content in foods rich in gluten and for the increased utilization of gluten. The invention further discloses a method for the management of gluten intolerance using composition comprising Bacillus coagulans and multi-enzyme complex in mammals.

Abstract: A probiotic-alcoholic beverage composition comprising Bacillus coagulans is disclosed herein wherein the said spore or vegetative cell of Bacillus coagulans exhibited high recovery, tolerability, compatibility and viability of spores and vegetative cells after brewing. Methods for brewing an alcoholic beverage composition comprising Bacillus coagulans wherein said spore or bacterium is added during pre-fermentation, during fermentation and post fermentation stages are also disclosed.

Abstract: The present invention discloses a method of isolating secondary metabolites, specifically arjunolic acid, from the calli and/or the suspension cultures derived from the pluripotent cambium tissue of Terminalia arjuna. The invention also discloses a method of inducing callus, establishing and maintaining suspension cultures of callus derived from the cambium of Terminalia arjuna for the isolation of secondary metabolites.

Abstract: The present invention discloses a novel fructophilic lactic acid producing bacteria Bacillus coagulans strain FF-7 (MTCC 25235) and the process of isolation and characterization of the bacteria.

Abstract: The present invention discloses a composition comprising heat inactivated spores and/or comprising heat inactivated vegetative cells of probiotic bacteria Bacillus coagulans, and a process for preparing the same. The invention also discloses a method of modulating immune function in mammals by activating macrophages, using a composition comprising Bacillus coagulans in the form of live or heat inactivated spore and/or vegetative cells.

Abstract: The present invention discloses a novel endophytic fungi, Ovatospora brasiliensis MTCC 25236 for the bioconversion of curcuminoids to Calebin-A and a method for its isolation from the rhizomes of Curcuma sp. The invention also discloses a method for the bioconversion of curcuminoids to Calebin-A using an endophytic fungi Ovatospora brasiliensis MTCC 25236 and bacterial species, Acinetobacter johnsonii and Pseudomonas putida.

Abstract: Disclosed is the hypolipidemic potential of Bacillus coagulans. More specifically the invention discloses the cholesterol lowering potential of Bacillus coagulans MTCC 5856 and therapeutic/biological indications thereof.

Abstract: The present invention discloses a stable probiotic composition comprising Bacillus coagulans individually and/or in combination with multi-enzyme complex for the utilization of lactose and therapeutic management of lactose intolerance. It also discloses a method for the management of lactose intolerance using composition comprising Bacillus coagulans individually and/or in combination with multi-enzyme complex.

Abstract: The present invention discloses a novel fructophilic lactic acid producing bacteria Bacillus coagulans strain FF-7 (MTCC 25235) and the process of isolation and characterization of the bacteria. The invention also discloses the biological applications/therapeutic use of fructophilic lactic acid producing bacteria in increased utilization of fructose from food stuff and in the managing disorders related to high fructose intake.

Abstract: The present invention discloses beverage compositions comprising probiotic Bacillus coagulans and water soluble prebiotic fibers that have been subjected to treatments under extreme stress, temperature and pressure conditions like brewing or aeration wherein the spore viability is maintained post said treatments.

Abstract: Disclosed are hair care compositions containing partially purified extracellular metabolite preparation from strains of Bacillus coagulans. Specifically, the uses of compositions containing extracellular metabolite preparation from a strain of Bacillus coagulans for increasing hair growth, inhibition of 5?-reductase and proliferation of follicle dermal papilla cells and in the management of androgenic alopecia, are disclosed.

Abstract: Disclosed are the skin care applications of a composition containing the partially purified extracellular metabolite isolated from Bacillus coagulans MTCC 5856. More specifically, the invention discloses the ability of the partially purified extracellular metabolite isolated from Bacillus coagulans MTCC 5856 to confer protection to the skin fibroblasts against UV induced cell damage and apoptosis, oxidative stress and inflammation.

Abstract: Disclosed is the use of partially purified extracellular metabolite isolated from Bacillus coagulans MTCC 5856 to prevent skin aging. More specifically the invention discloses the anti-collagenase, anti-elastase, anti-glycation activity and enhancement of TGF-?, epidermal growth factor and hyaluronic acid expression in human dermal fibroblasts, of extracellular metabolites isolated from Bacillus coagulans MTCC 5856.

Abstract: The present invention discloses a novel fructophilic lactic acid producing bacteria Bacillus coagulans strain FF-7 (MTCC 25235) and the process of isolation and characterization of the bacteria. The invention also discloses the biological applications/therapeutic use of fructophilic lactic acid producing bacteria in increased utilization of fructose from food stuff and in the managing disorders related to high fructose intake.

Abstract: Disclosed are the methods and compositions for the reduction of intestinal gas/flatulence. Specifically a method for reducing flatulence using a composition containing probiotic bacteria Bacillus coagulans MTCC 5856 is disclosed. More specifically, the invention discloses a method for inhibiting the growth of microorganisms that facilitate the production of intestinal gas, using a composition containing probiotic bacteria Bacillus coagulans MTCC 5856.

Abstract: The present invention discloses a stable probiotic composition comprising Bacillus coagulans individually and/or in combination with multi-enzyme complex for the utilization of lactose and therapeutic management of lactose intolerance. It also discloses a method for the management of lactose intolerance using composition comprising Bacillus coagulans individually and/or in combination with multi-enzyme complex.

Abstract: The present invention discloses the potential of probiotic bacteria Bacillus coagulans individually or in combination with multi-enzyme complex for reducing gluten content in foods rich in gluten and for the increased utilization of gluten. The invention further discloses a method for the management of gluten intolerance using composition comprising Bacillus coagulans and multi-enzyme complex in mammals.

Abstract: Disclosed are compositions containing at least 10% w/w or above of 1-O-galloyl-?-D-glucose (?-glucogallin) which additionally comprising of about 10% w/w to greater than 60% w/w total mucic acid gallates including mucic acid 1,4-lactone 5-O-gallate, mucic acid 2-O-gallate, mucic acid 6-Methyl ester 2-O-gallate, mucic acid 1-Methyl ester 2-O-gallate and ellagic acid, and a probiotic bacteria Bacillus coagulans MTCC 5856, individually or in combination for inhibiting the growth and managing infections of Helicobacter pylori.